References
- Machlowska J, Baj J, Sitarz M, et al. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;11(21): 4012.
- Sexton RE, Al Hallak MN, Diab M, et al. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 2020;39:1179–1203.
- Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer. Lancet. (London, England). 2020;396:635–648.
- Tang T, Zhang L, Li C, et al. Gastric and adrenal metastasis from breast cancer: case report and review of literature. Medicine (Baltimore). 2020;99:e18812.
- Han J, Kong H, Wang X, et al. Novel insights into the interaction between N6-methyladenosine methylation and noncoding RNAs in musculoskeletal disorders. Cell Prolif. 2022;e13294. DOI:10.1111/cpr.13294
- Wu X, Deng Z, Liao X, et al. Establishment of prognostic signatures of N6-Methyladenosine-related lncRNAs and their potential functions in hepatocellular carcinoma patients. Front Oncol. 2022;12:865917.
- Xie P, Yan H, Gao Y, et al. Construction of m6A-Related lncRNA prognostic signature model and immunomodulatory effect in glioblastoma multiforme. Front Oncol. 2022;12:920926.
- Zhang W, Zhang Q, Xie Z, et al. N (6) -methyladenosine-related long non-coding RNAs are identified as a potential prognostic biomarker for lung squamous cell carcinoma and validated by real-time PCR. Front Genet. 2022;13:839957.
- Wu C, Lin W, Fu F. Long non-coding RNA DLX6-AS1 knockdown suppresses the tumorigenesis and progression of non-small cell lung cancer through microRNA-16-5p/BMI1 axis. Transl Cancer Res. 2021;10(8):3772–3787.
- Gong J, Ma L, Peng C, et al. LncRNA MAGI2-AS3 acts as a tumor suppressor that attenuates non-small cell lung cancer progression by targeting the miR-629-5p/TXNIP axis. Ann Transl Med. 2021;9(24):1793.
- Huang H, Weng H, Chen J. m(6)A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell. 2020;37:270–288.
- Ma Z, Ji J. N6-methyladenosine (m6A) RNA modification in cancer stem cells. Stem Cells. 2020;38(12):1511–1519. Dayton, Ohio.
- Zhu ZM, Huo FC, Pei DS. Function and evolution of RNA N6-methyladenosine modification. Int J Biol Sci. 2020;16:1929–1940.
- Wang YN, Yu CY, Jin HZ. RNA N(6)-Methyladenosine modifications and the immune response. J Immunol Res. 2020;2020:6327614.
- Jin L, Chen C, Yao J, et al. The RNA N(6) -methyladenosine modulator HNRNPA2B1 is involved in the development of non-small cell lung cancer. Clin Exp Pharmacol Physiol. 2022;49:329–340.
- Zhao T, Wang M, Zhao X, et al. YTHDF2 inhibits the migration and invasion of lung adenocarcinoma by negatively regulating the FAM83D-TGFβ1-SMAD2/3 Pathway. Front Oncol. 2022;12:763341.
- Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17(12):3077–3079.
- Huang S, Guo Y, Li Z, et al. A systematic review of metabolomic profiling of gastric cancer and esophageal cancer. Cancer Biol Med. 2020;17(1):181–198.
- Yuan LW, Yamashita H, Seto Y. Glucose metabolism in gastric cancer: the cutting-edge. World J Gastroenterol. 2016;22:2046–2059.
- Li L, Li Z, Qu J, et al. Novel long non-coding RNA CYB561-5 promotes aerobic glycolysis and tumorigenesis by interacting with basigin in non-small cell lung cancer. J Cell Mol Med. 2022;26(5):1402–1412.
- Wang Y, Lu JH, Wu QN, et al. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Mol Cancer. 2019;18:174.
- Liu H, Xu Y, Yao B, et al. A novel N6-methyladenosine (m6A)-dependent fate decision for the lncRNA THOR. Cell Death Dis. 2020;11(8):613.
- Wu Y, Yang X, Chen Z, et al. m(6)A-induced lncRNA RP11 triggers the dissemination of colorectal cancer cells via upregulation of Zeb1. Mol Cancer. 2019;18:87.